10-Q: Synergy CHC Corp. Reports Net Income of $876,264 for Q1 2025, Despite Revenue Decline

Synergy CHC Corp. announces a profitable first quarter for 2025, driven by a license agreement and cost management, despite a decrease in product sales revenue.

Summary

• Synergy CHC Corp. reported a net income of $876,264 for the three months ended March 31, 2025, compared to $580,530 for the same period in 2024.
• Total revenue decreased to $8,170,534 from $9,411,863, primarily due to a decrease in nutraceuticals revenue, offset by $1,500,000 in license revenue.
• Cost of revenue decreased to $2,006,513 from $2,637,139, reflecting the decrease in revenue.
• Selling and marketing expenses decreased to $2,876,271 from $3,584,677 due to lower revenue and improved management of promotions.
• General and administrative expenses decreased slightly to $1,306,714 from $1,348,385.
• The company's EBITDA increased to $1,979,624 from $1,850,645.
• As of March 31, 2025, the company had $177,882 in cash and cash equivalents and $100,000 in restricted cash.
• The company is focusing on growing its nutraceuticals and ready-to-drink verticals and is evaluating strategic acquisitions.
• The company's disclosure controls and procedures were not effective as of the end of the period covered by this Quarterly Report.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the company achieved net income and increased EBITDA, revenue declined. The ineffective disclosure controls are a concern. Overall, the sentiment is neutral.

Positives

• The company achieved net income of $876,264, an increase compared to the same period last year.
• The company generated $1,500,000 in revenue from a license agreement.
• EBITDA increased to $1,979,624.
• Selling and marketing expenses decreased due to improved management of promotions.
• General and administrative expenses decreased due to improved management of operating costs.

Negatives

• Total revenue decreased from $9,411,863 to $8,170,534.
• Nutraceuticals revenue decreased due to a non-repeating new product sell-in to one customer in 2024.
• The company's disclosure controls and procedures were not effective as of the end of the period covered by this Quarterly Report.

Risks

• The company's disclosure controls and procedures were not effective as of the end of the period covered by this Quarterly Report.
• The company has a significant amount of debt, including related party debt, which could impact its financial flexibility.
• The company relies on a few major customers and suppliers, which could create concentration risks.
• The company's future performance depends on its ability to successfully launch new products and expand into new markets.
• The company's ability to utilize net operating loss carryforwards is uncertain due to potential limitations.

Future Outlook

The company intends to grow organically by developing and launching new products and expanding into new markets, particularly focusing on increased distribution for its ready-to-drink beverage. The company also intends to grow through strategic acquisitions.

Industry Context

The company operates in the consumer health care and nutraceuticals industry, which is characterized by increasing demand for health and wellness products. The company faces competition from other players in the market, including established consumer health companies and emerging brands.

Comparison to Industry Standards

• It is difficult to compare Synergy CHC Corp.'s results directly to industry standards without more specific information on comparable companies and projects.
• However, the company's gross profit margin of 75% is relatively high, suggesting a strong pricing strategy or efficient cost management.
• The company's focus on growing its nutraceuticals and ready-to-drink verticals aligns with current industry trends.

Corporate Governance

Related Party Transactions

• The Company paid consulting fees through March 2025 to a company owned by Mr. Jack Ross, Chief Executive Officer of the Company.
• The Company advanced $180,000 and $165,687 in prepaid consulting fees during the three months ended March 31, 2025 and 2024, respectively.
• During the three months ended March 31, 2025 and 2024, the Company was advanced $135,000 and $1,400,000, respectively, in the form of a short-term note from a related party.
• The Company entered into transactions with a related party controlled by the CEO during prior years for a pass through and allocation of expenses and reimbursements.
• The Company has a loan receivable from a related party controlled by the CEO.
• The Company has notes payable to Knight Therapeutics, a related party, including accrued interest and royalties.

Stakeholder Impact

• Shareholders: The company's profitability and growth prospects impact shareholder value.
• Employees: The company's financial performance affects employee compensation and job security.
• Customers: The company's ability to provide quality products and services impacts customer satisfaction.
• Creditors: The company's ability to repay its debts impacts its relationship with creditors.
• Suppliers: The company's financial stability affects its ability to pay suppliers.

Next Steps

• The company intends to organically grow its current product lines by developing and launching new products and expanding into new markets.
• The company is working on increased distribution for its recently launched ready-to-drink beverage.
• The company intends to grow further through additional strategic acquisitions and continues to evaluate opportunities.
• The company will hold its 2025 Annual Meeting on June 18, 2025, to elect directors, ratify the appointment of auditors, approve an amendment to the equity incentive plan, and approve an amendment to the Articles of Incorporation to provide authority to issue up to 1,000,000 shares of preferred stock.

Key Dates

Keywords

Synergy CHC Corp, financial results, Q1 2025, net income, revenue, EBITDA, nutraceuticals, license agreement, debt, FOCUSfactor, Flat Tummy